Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in children and adolescents with BCP-ALL
NCT04723342Recruiting
- Sponsor
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Start
- Feb 2020
- Primary completion
- Dec 2022
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of blinatumomab in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) (2 arms), sponsored by Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Primary endpoints: Minimal residual disease at 1 year and Event-free survival at 5 years. Started Feb 2020; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
Beyond the preview
Go deeper on NCT04723342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04723342.